

Charity Registration No. 1183890 (England and Wales)

Charity Registration No. SC049802 (Scotland)

Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE
ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023



www.leukaemiacare.org.uk

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons	Lady Penny Mountbatten Beverley Warboys	
Trustees	Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis Ms E Wilson (Vice Chair) Ms Kate Stallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland Ms Carina Patterson Helen Knight Dr Sarah Searle	
President	Dr Richard Taylor	
Vice Presidents	Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin	
Senior Management Team		
Chief Executive Officer	Colin Dyer	(appointed 02/04/2024)
Chief Executive Officer	Zack Pemberton-Whiteley	(resigned 30/11/2023)
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz	
Communications and Fundraising Director	Nicole Scully	
Medical Advisory Panels	As described in the Trustees' Report	
Secretary	Monica Izmajlowicz	
Charity number (England and Wales)	1183890	
Charity number (Scotland)	SC049802	
Company number	11911752	
Website	www.leukaemiacare.org.uk	
Registered office	One Birch Court Blackpole East Worcester WR3 8SG	

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Auditor	Kendall Wadley LLP Granta Lodge 71 Graham Road Malvern Worcestershire WR14 2JS
Bankers	Barclays Bank Plc 54 High Street Worcester WR1 2QQ
Solicitors	Harrison Clark Rickerbys 5 Deansway Worcester WR1 2JG
Investment advisors	Titan Private Wealth Limited 2 Greengate Cardale Park Harrogate HG3 1GY CCLA Senator house 85 Queen Victoria Street London EC4V 4ET Brewin Dolphin 12 Smithfield Street London EC1A 9BD

LEUKAEMIA CARE

CONTENTS

	Page
Trustees' report	1 - 20
Statement of trustees' responsibilities	21
Independent auditor's report	22 - 24
Statement of consolidated financial activities	25
Statement of financial activities - charity	26
Consolidated Balance sheet	27 - 28
Charity Balance sheet	29 - 30
Statement of cash flows	31
Notes to the financial statements	32 - 55

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) *FOR THE YEAR ENDED 31 DECEMBER 2023*

The trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable group's memorandum & articles of association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

About us

Leukaemia Care is the UK's leading leukaemia charity. For over 50 years, we have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support.

We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

Purpose

The charity's objects are set out in its Articles of Association:

1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders.
2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long-term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - What we are doing to make that vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families too. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments.

But most importantly, we bring people together and unite them behind our common goal. Together, we will create the future we all believe in.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Why our work is important

To paint a picture of the scale of the issue across the UK:

- Leukaemia is the 12th most common form of cancer and 12th biggest cancer killer.
- Every year, 10,000 people are diagnosed with leukaemia in the UK.
- Every year, 5,000 people die from leukaemia in the UK.
- Every year 6,000 people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
- Over 50,000 people are living with leukaemia in the UK.
- There are 34,000 people living with MDS or MPN in the UK.

Our Strategic Goals

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner:

1. Improving diagnosis – through awareness and early detection.
2. Ensuring everyone receives high quality information, advice and support.
3. Tackling issues that impact people's lives.
4. Advancing treatment and care.
5. Creating a narrative to better reflect the reality people experience. But we need your help. If you believe in the future we are trying to create and want to help us get there faster, please get involved.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Leukaemia Care provides public benefit as a charity through all the charitable information, advice and support service areas detailed above. The Trustees have complied with their duty in accordance with the Charities Act 2011 to have due regard to the Charity Commission's guidance when reviewing the charity's aims and objectives, approving funding for projects and services, and in planning and undertaking current and future activities. Taking the Charity Commission's guidance into consideration, the Trustees are satisfied that our public benefit requirements have been met.

As examples, our work delivers public benefit by providing information, advice and support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our HashtagSpot Leukaemia campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed free training on aspects of caring for blood cancer patients thus enhancing their care.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Achievements and performance Executive summary

2023 was officially the Year of the Unicorn. Two years in the planning, Unicornfest – Leukaemia Care's public art trail in Bristol was a challenging new endeavour to raise funds for and raise awareness of leukaemia and Leukaemia Care.

In terms of awareness, people of all ages were engaged in the city of Bristol – throughout the trail and with the Farewell Festival – with overwhelmingly positive feedback received. Some of the specific numbers include: 339,083 scans of unicorns by visitors, 25,900 downloads of the app, 489,657 website views, 9,000 farewell festival attendees and repeated press coverage including BBC, ITV and many other publications. As a result, 67% of trail goers said they were more aware of Leukaemia Care because of the trail, and 52% said they were likely to support Leukaemia Care in the future.

It was a strong year for service delivery with investment from reserves allowing us to address rising demand for our patient services as shown in the Charitable Programmes Summary below. Recognising the importance of high- quality information to patients, families and the healthcare professionals looking after them, and our expanding portfolio of booklets, we formed a dedicated information team and appointed an experienced Information Manager to help us refine our strategy.

We continue to work closely with Leukaemia UK on raising awareness of the signs and symptoms of leukaemia with our Spot Leukaemia campaign and are an active member of the influential Blood Cancer Alliance.

Our engagement with supporters has improved, with over 400 respondents in our annual survey. We are grateful that so many people took the time to complete it and give us their feedback – we will be using it to inform our strategy in 2024 and beyond.

Fundraising continues to be challenging, with the art trail and other areas not reaching anticipated levels and developing income streams needing longer to come to fruition. This meant a greater investment from reserves than anticipated for 2023 and will be reflected in plans for 2024 and 2025. The Trustee Board remain committed to investing in services and growing income to meet increasing demand. However, when it became apparent that we were not going to reach those anticipated fundraising levels, savings in expenditure began to be planned across the charity which may also impact work in 2024.

After nine years of service in various roles, our CEO, Zack Pemberton-Whiteley left for new opportunities in December. Our COO and Director of Comms and Fundraising stepped in as joint Interim CEOs, and a new CEO was appointed in April 2024.

Charitable Programmes Summary

A breakdown of achievements against our five organisational goals is available in our Strategic Update section below. All funds assigned to Leukaemia Care's charitable services during the year were consistent with those goals set out in our *The Future We Will Create Together* strategy (published in 2022 and available at www.leukaemiacare.org.uk). Examples of the allocation of those funds and the continuing increase in demand for our patient services include:

- The provision of essential information with 34,259 information booklets (28,800 in 2022) either ordered as printed copies or downloaded directly from the Leukaemia Care website, and 2,905 welcome packs (1,005 in 2022) sent to people newly engaged with the charity.
- The charity's information helpline supported 1,192 people (compared to 906 in 2022).
- The work of our Welfare Officer who helped 301 people (217 in 2022), and our Advocacy Officer who supported 204 people (266 in 2022). 819 hardship grants (465 in 2022) were made and a further 30 families were given financial or accommodation support for CAR-T treatment, thanks in no small part to our partnership with Dalata Hotels.
- Our Hospital Support Workers helped 583 people (199 in 2022), a further 2,397 people (1,911 in 2022) attended 39 support groups, and 4,900 people were connected through our online forums (4,333 in 2022).
- The Leukaemia Care Buddy scheme matched 148 people (131 in 2022), while counselling was provided for 63 patients (56 in 2022).

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

- In terms of reach, our Why Spot Leukaemia video was viewed 1.85m times, and we reached 1.7billion people through 147 national and 323 regional pieces of media coverage along with our extensive online activity.

Financial summary

- 67 per cent of the charity's income was allocated to our charitable services and projects in 2023 compared to 56 per cent in the previous year.
- The total income raised during the year was £2,263,249 (£2,139,494 in 2022) against expenditure of £2,860,835 (£1,979,542 in 2022).
- Investment of £566,954 was made from the strategic implementation fund against a planned deficit of £468,272 – which was £98,682 higher due to lower than anticipated performance in some areas of fundraising.
- Total reserves stand at £2,573,092 of which £148,342 are restricted and £2,424,750 are unrestricted. Within the unrestricted funds is a designated fund called the 'Strategic Implementation Fund' which, at year end, stands at £227,528. This fund was designated to support the two-year strategy agreed by the Board of Trustees in January 2024.

Strategic update for 2023 including our plans for 2024

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner. For more information on our five goals, please visit our website www.leukaemiacare.org.uk

This report sets out Leukaemia Care's achievements in each of these priority areas during 2023, along with the charity's goals for the year ahead.

Goal 1: Improving diagnosis – through awareness and early detection

We achieve this through our annual SpotLeukaemia campaign, targeting awareness days like World Leukemia Day and through our education work with GPs and other healthcare professionals.

In 2023 we continued our collaboration with Leukaemia UK on the Spot Leukaemia campaign, focusing on raising awareness of the symptoms of leukaemia. We soft-launched at the end of August with our new creative video (Why Spot Leukaemia) which encourages people to access their inner child and ask "why" when they notice symptoms such as fatigue, repeated infections, bruising and bleeding, to then see their GP and ask for a blood test. The video was viewed 1.85 million times.

In 2024, we will review the Spot Leukaemia collaboration with Leukaemia UK, now in its fourth year, to determine its long-term direction and impact.

Throughout the year, we ran mini campaigns on awareness days such as World Leukemia Day, MDS Day, Know AML Day and World Cancer Day. We took part in 11 blood cancer awareness days sharing 50 patient stories across different leukaemias, MDS and MPN. World Leukemia Day (4 September) which was launched by Leukaemia Care in 2020 in partnership with worldwide patient advocate groups reached 28.3 million people in 2023 (30.1 million in 2022) on social media.

Uptake of our GP online learning modules via the Royal College of General Practitioners (RCGP) and Gateway C increased in 2023 (233 in 2022 vs. 340 in 2023). A further 87 GPs attended our two webinars, which were both rated as very good by attendees. We continued to attend and exhibit at conferences aimed at GPs such as the Best Practice, Guidelines and the RCGP annual conference with all contacts receiving follow-up information from us.

In 2024, we will do a complete review of our GP education to produce recommendations on what we could do better to raise awareness of leukaemia signs and symptoms with GPs.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Goal 2: Ensuring everyone receives high quality information, advice and support

Leukaemia and blood cancer is highly complex. We know that at diagnosis people are significantly less likely to understand what is wrong with them than for other forms of cancer. Many are left worried and confused.

We know that high quality information, advice and support is key. Whilst most people receive information about their blood cancer, few receive information about emotional, practical and financial support.

This area of work covers our core frontline services for patients and their families. Our written information (hard copy and online), videos, podcasts, webinars and conferences. Our advice service incorporates the helpline, WhatsApp, email, advocacy casework and welfare advice, and hospital hubs. Our support services; support groups, online forums, one to one buddy support, financial grants, counselling and free wills.

As the range and volume of patient information produced by Leukaemia Care increases, we appointed an Information Manager to ensure we continue to provide good quality information.

In 2023, we focused on updating our patient information as and when it came up for review. We updated our MDS booklet in collaboration with MDS UK and released a factsheet alongside it.

We continue to offer our existing booklets alongside the new formats and in 2023, distributed 15,706 (13,862 in 2022) hard copies and 18,553 (15,118 in 2022) free copies were downloaded from our shop. We also maintained our accreditation with the PIF Tick scheme for patient information, ensuring our information continues to be produced and reviewed in a robust way.

We recognize that people like to access information in different formats, not just booklets, and that many would like an introduction to our services. We sent out 2,905 (1,005 in 2022) Welcome Packs introducing people to our services and signposting them to our booklets, blogs, monthly podcast, videos and webinars.

We ran 15 (20 in 2022) webinars on a variety of topics which were all recorded so they can be accessed time and time again for people looking for information and debate on key topics such as women's health, CLL and living well on watch and wait, our "understanding" series (hair cell leukaemia, MPN, ALL, CML), vaccinations when living with leukaemia, MPN and MDS. Our webinars were viewed 11,429 (16,352 in 2022) times on social media.

Alongside our information, we offer the opportunity to seek advice and support from our clinical nurse specialists, trained advocates and welfare advisors. We provided 1,192 people (906 in 2022) with timely advice and support via our helpline, WhatsApp and email with an average feedback score of 4.75 out of 5.

Our Advocacy Caseworker supported 204 people (266 in 2022) with issues such as employment rights, early retirement, travel insurance, COVID-19 related-queries and non-COVID vaccines. They work closely with our Welfare Officer as many people have varied and complex needs that also affect finances.

The number of advocacy queries has been lower overall this year in comparison to 2022 because of a fall in the number of COVID-19 queries that we receive, as some patients become more confident in managing their risk without our guidance. Despite a lower number of cases, there has been an increase in more complex queries that have required more in-depth casework, working directly with patients to support them with issues such as employment and housing.

Our Welfare Officer supported 301 (217 in 2022) people with most queries being classed as major i.e. complex, helping people to apply for benefits, support with housing, challenge benefits decisions, apply for grants of money and goods and processing applicants for our Financial Hardship Fund, Exceptional Hardship Fund and CAR-T Away from Home Fund.

"This PIP approval is a game-changer, opening doors to assistance from my local council and occupational therapists. I cannot express enough gratitude for your unwavering support. Without your and Leukaemia Care's guidance, this wouldn't have been achievable. Your encouragement and advice have been an absolute lifeline."
Patient

Towards the end of 2023, we set up four new hubs in Gwent, Plymouth, Bournemouth, and Norfolk. We also ran a pilot hub with the Queen Elizabeth Hospital in Birmingham for a year which sadly was not extended.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our other locations are Solihull Hospital (West Midlands), Heartlands Hospital (Birmingham), St James Hospital (Leeds), Southampton General, University of Bristol Hospital, The Christie (Manchester), University College London Hospital, and Freeman Hospital, Newcastle.

Our hospital support workers provide emotional support, information and advice to patients and their families within haematology departments and on hospital wards, at diagnosis and throughout their treatment. In 2023, we supported 583 people (199 in 2022), in person and by phone as needed by the hospitals.

We ran 39 support groups (in person, hybrid and online only) supporting 2,397 people in 2023 (1,911 in 2022). Our specialist online support groups are well received especially by those with rarer leukaemias.

We also ran an online forum via HealthUnlocked and closed Facebook groups that collectively supported 4,900 (4,333 in 2022) people.

Our buddy service matches patients and families with people who have a similar diagnosis for emotional support. In 2023, we matched 148 (131 in 2022) patients for long-term or short-term buddying with some volunteer buddies supporting multiple patients.

"I had a really good chat with [my buddy] last night and gave me a good insight into what we are both going through. I'm really glad that I took up your service of support." **Patient**

We recognise that a leukaemia diagnosis can have a negative impact on people's finances especially during a cost-of-living crisis. In 2023, we awarded 819 (465 in 2022) hardship grants of between £100 to £200 and 12 exceptional hardship grants of up to £1,000. Our Cost-of-Living grants are run in partnership with Leukaemia UK.

Our CART-T Away from Home service provides patients undergoing CAR-T treatment and their families with access to paid hotel rooms and a £500 grant towards increased costs. This is a partnership with our corporate partner, the Dalata Hotels Group. In 2023, we supported 30 families with a combination of hotel stays (8 with an average stay of 24 days) and financial grants.

Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or non-existent. In 2023, we supported 63 people (56 in 2022) seeking support with issues such as bereavement, coping with a diagnosis either as a patient, parent or child, coping with chronic leukaemia, and managing anxiety following a relapse.

We believe everyone diagnosed with a potentially life limiting illness such as leukaemia should have the chance to make a will. In 2023, 61 (53 in 2022) people made a will using our free wills service with 30 choosing to leave a gift in their will to Leukaemia Care although there is no obligation to do so.

In 2024, we will continue to expand our network of hospital hubs to ensure we support more people at diagnosis and throughout their blood cancer pathway. We will grow our Information Team and explore how we can make our information more accessible. We will review our support groups to ensure we reach as many people as possible and for those who cannot attend support groups, offer them a buddy. At a time when many organisations struggle to provide financial grants, we will continue to provide them while recognising that this is often only a brief respite from ongoing hardship because of a leukaemia diagnosis.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Goal 3: Tackling issues that impact people's lives

This area of our work covers our advisory panels (medical and patient), our patient experience research, our policy and public affairs, campaigns and external advocacy projects.

Our medical and patient advisory panels provide feedback on not only our strategic plans but also our day-to-day work. We have 82 healthcare professionals including specialists in the four main leukaemias as well as MDS, MPN and rare leukaemias. These include consultant haematologists, clinical nurse specialists, GPs, psychologists and district general hospital doctors. Our patient advisory panel of 64 includes acute and chronic leukaemia patients, those with rare leukaemias, MDS and MPN.

In 2024, we will investigate new ways of engaging with our panels to ensure that we gather views in a timely manner. This will not be limited to online meetings but also incorporate quick polls and lengthier surveys. We will strive to ensure our patient panels reflect the diverse blood cancer community we serve and offer other opportunities to volunteer should members feel they no longer wish to serve on the panels.

When faced with a diagnosis, many will often think about the impact on a person's physical or mental health. Whether it's time off work for treatment causing a loss of wages, increased heating bills to warm through the home to cope with the effects of treatment or inflated food costs to help maintain a well-balanced diet, the financial implications are far and wide.

These are just some of the hidden costs that come with a leukaemia diagnosis but are often forgotten about. That's the Leukaemia Levy – the hidden tax, the cost of leukaemia, even when you are being treated and cared for by the NHS.

In March 2023, we launched our Hashtag Leukaemia Levy campaign to raise awareness and secure financial support for those affected by a diagnosis. Our three asks were: a Government Hospital Travel Fund, an extension to the support provided by the energy price guarantee and the energy bills scheme and increased financial assistance from energy companies.

We asked people to show their support by signing a petition standing behind these asks. We sent a letter to the Chancellor and Prime Minister, hand-delivering the letters to their respective doors on Downing Street. Mark Tami MP presented our petition to the house of Commons asking members to join us in urging the Government to provide more support for leukaemia patients.

In 2024, we will work with other charities and organisations collectively to continue to address the financial challenges faced by cancer patients.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Goal 4: Advancing treatment and care

This area covers our engagement with healthcare professionals – providing training and raising awareness of our services as well as our work on improving access to treatments.

Our Regional Coordinators raise awareness of our services within hospitals across the UK and in 2023, conducted 630 meetings both in person and online to engage with a diverse range of healthcare professionals working with blood cancer patients. Our coordinators successfully engaged with 252 health care professionals new to our services.

We awarded five bursaries to nurses seeking to improve their skill and knowledge of patient care through courses at the Royal Marsden Hospital and Coventry University.

We offer eight free online courses for nurses ranging from 1 to 4 hours. Four were removed from circulation pending updates. Topics covered are CAR-T, emergencies in leukaemia, end of life and acute leukaemia, GVHD, supportive care, MPNs, understanding blood and its components, diagnosis of leukaemia, and epidemiology, aetiology and risk factors. The average feedback score from users remains consistently high at 4.9/5 (4.25/5 in 2022) with 265 new subscribers (217 subscribers in 2022). In 2024, we will publish a new course on genetics in acute myeloid leukaemia. Due to resource limitations, as our courses reach their review date, they will be removed from circulation until they can be updated.

In 2023, we launched two new forums for MPN and acute leukaemia nurses alongside our existing chronic lymphocytic leukaemia forum. In 2023, 126 healthcare professionals (52 in 2022) attended to share updates from scientific and clinical meetings and best practice in patient care.

Leukaemia Care have committed to be actively involved in all relevant Health Technology Appraisals for leukaemia, MDS and MPN to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. In 2023, we were involved at every stage of the health technology appraisal process in 98% of appraisals and were involved in a stage of the process in 100% of appraisals. We secured patient experts for 67% of appraisals with 89% of appraisals also having input from patients via surveys.

Goal 5: Creating a narrative to better reflect the reality people face

Patient stories, press and social media all play a critical role in ensuring that patients and their families as well as the public understand the reality of living with leukaemia.

Seventy-two people shared their story with us to support others and raise awareness of the challenges they face with half of these having benefited from our services. Forty-four people keen to give back and raise awareness of the support available from Leukaemia Care provided testimonies to be used to encourage people to reach out for help.

In 2023, we received 147 (56 in 2022) pieces of national and 323 (651 in 2022) pieces of regional press coverage with an estimated reach of over 1.7 billion (1.4 billion in 2022).

Our symptoms of leukaemia information and blogs continue to be our most visited pages on our website especially on swollen lymph nodes and bruising. An accessibility toolbar has now been deployed on the website which offers translation in over 160 languages as well as accessibility features such as increasing the size of text and an audio function.

In 2024, we will continue to review our webpages focusing on our information for patients through the creation of hubs for different leukaemia types.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Fundraising summary

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (<https://www.fundraisingregulator.org.uk/>) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2023, the charity received no suppression requests through the Fundraising Preference Service and no fundraising complaints.

Our complaints procedure can be found on our website <https://www.leukaemiacare.org.uk/about-us/>

After concluding 2022 on a positive note, having raised over £2 million for the first time, 2023 posed fundraising challenges and while fundraising income increased, the costs of raising those funds also saw a significant rise. The positive impact of that further investment in fundraising is expected to be seen in the coming years.

Reliable income streams such as legacies and pharmaceutical grants were lower than anticipated, and while we benefited from £165,303 (£411,669 in 2022) from gifts in wills – this was a significant decrease when compared to previous years.

The Unicornfest art trail was an excellent public event raising awareness of leukaemia and Leukaemia Care, however the return on time invested was lower than expected despite the fact that the auction raised a respectable £146K – the single highest amount raised for the charity in a single day.

We had some success with new initiatives such as our first ever matched donation campaign run during Blood Cancer Awareness Month in September made possible by a long-standing supporter and major donor which raised £22,524. Our corporate partnership with Dalata Hotels Groups allowed us to expand our CAR-T Away From Home service as hotel employees worked hard to raise funds. And we exceeded targets in some of our running and challenge events including the London Marathon in which we had 117 runners. Grants and trusts exceeded its target and includes support from Leukaemia UK towards our cost of living with leukaemia grants. We successfully launched our first joint fundraising and support initiative, linking our Bereavement service to In Memory fundraising. This integration resulted in a historical high for In Memory income, exceeding predictions by £25,000. Further growth is anticipated as we strengthen our work in this area. We also started work on our BBC Lifeline appeal which will air in early 2024 and launched our Christmas giving campaign "Snow Much Love" which will run into 2024.

Please see below for more details on the grants received from the pharmaceutical industry and grants and trusts foundations.

In 2024, we will focus on consolidating work done to date focusing on building our legacy, corporate and major donor income.

Pharmaceutical grants

Leukaemia Care collaborates with the pharmaceutical industry to ensure that the interests of patients are considered during the development of new drugs and treatments. Our patient advisory work plays an important role in making sure treatments are thoroughly appraised and person-centred before they are made available to the public. As a way of helping us remain secure and to continue to be effective in our work with patients, many pharmaceutical companies provide us with funding throughout the year. This funding is always received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care's own Code of Practice (see our website).

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

To ensure that we remain financially independent, limits are placed on all types of grant income. We do not allow the level of funding received from the pharmaceutical industry to exceed 25% of our total annual income, nor do we allow the funding received from any individual company to exceed 10% of our total annual income.

In 2023 we were grateful for the following support from pharmaceutical companies which totaled £214,472. We also received a further £9,479.11 in honorariums. Please note, this is funding that was received in 2023 – any funding that was intended for 2023 but not received until 2024 will be acknowledged in the annual report and accounts for 2024.

Abbvie - £15,800 towards improving the accessibility of our Information Programme
Amgen - £5,000 in core funding
AstraZeneca UK - £15,000 towards our work in early diagnosis
Autolus - £10,000 in core funding
Bristol Myers Squibb - £15,000 in core funding
GlaxoSmithKline - £15,000 towards our Counselling Service
Incyte - £15,000 towards our work in early diagnosis
Jazz Pharmaceuticals - £20,000 towards our work in early diagnosis
Kura Oncology - £10,000 in core funding
Kyowa Kirin - £5,000 in core funding
Novartis - £25,000 towards our work in early diagnosis
Pleco Therapeutics - £8,672.27 in core funding
Servier - £5,000 in core funding
Takeda Pharmaceuticals - £50,000 in core funding

Grants and trusts

Leukaemia Care receives no statutory funding, but it does receive grants from independent trusts and other funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We would like to thank the following funders who kindly pledged their support in 2023. Please note, this is grant funding that was received in 2023 – any funding that was pledged for 2023 but not received until 2024 will be acknowledged in the annual report and accounts for 2024.

Acute Leukaemia Advocates Network
The Alice Ellen Cooper-Dean Charitable Foundation
AMW Charitable Trust
The Barbour Foundation
The Big Life Group
Birmingham Hospital Saturday Fund
Brighton District Nursing Association Trust
The Burford Trust
The C L Lloyd Charitable Trust
The de Brye Charitable Trust
Doris Field Charitable Trust
The Earl Fitzwilliam Charitable Trust
The Edward and Dorothy Cadbury Trust
The Frank Litchfield Charitable Trust
Fullagar Charitable Trust
The Helen Jean Cope Charity
The J Reginald Corah Foundation Fund
The James Tudor Foundation
John James Bristol Foundation
The Livewell Foundation
The Medicash Foundation
The Meikle Foundation
The Michael and Anna Wix Charitable Trust
The National Lottery Community Fund
The Nisbet Trust
Norwich Charitable Trusts
The Pennycress Trust
Pilkington Charities Fund

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The R C Snelling Charitable Trust
The Roger & Douglas Turner Trust
The Rothley Trust
The Rowlands Trust
The Roy Proctor Foundation
Santa Barbara Heights Trust
Schroder Charitable Trust
The Shanly Foundation
Sir John Eastwood Foundation
The Sovereign Healthcare Charitable Trust
The Squire Patton Boggs Trust
Sutton Coldfield Charitable Trust
The Tyne & Wear Community Foundation
W A Cargill Fund
The W E Dunn Trust
The Walter Guinness Charitable Trust
The Wilmcote Chariturst

Grant making by Leukaemia Care

Leukaemia Care has five grant making streams: the Cost of Living with Leukaemia Fund (formerly the Financial Hardship Fund), the Exceptional Hardship Fund, the Leukaemia Counselling Fund, and the CAR-T Away from Home Service (launched in 2022) and nurse bursaries (relaunched in 2023). These contribute towards addressing the recommendations made in our Living with Leukaemia reports which inform our strategic aims.

Cost of Living with Leukaemia Fund

This fund provides grants of up to £200 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month.

Exceptional Hardship Fund

Applicants who have received the Financial Hardship Fund of £200 within the year and are assessed as experiencing exceptional hardship are considered for an additional grant of up to £1,000. They are likely to be facing multiple challenges alongside a leukaemia diagnosis such as no recourse to public funds, homelessness or poor housing, significant mental health issues, care for a disabled dependant (adult and/or child) etc.

The Leukaemia Counselling Fund

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

CAR-T Away from Home Service

CAR-T (Chimeric Antigen Receptor) cell therapy is a type of treatment for leukaemia that has revolutionized the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia (ALL) but is expected to change the way other forms of leukaemia patients are treated in the future. The way the therapy is delivered means that patients often have long periods of waiting and spending time near to hospital to receive the treatment.

People can apply for accommodation, grant funding or both with one grant per family. This grant is only open to those currently going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund does not have a closing date and funds are allocated on a first-come first-served basis until the fund is depleted.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Thanks to our hotel partner Dalata, we can offer free accommodation in one double or twin room per family per stay for up to 30 days. This is booked and arranged by Leukaemia Care, and we must know the dates in advance. This cannot be exchanged for money, vouchers, or another hotel.

We will also pay up to £500 in a cash grant to help with other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc.

Nurse Bursaries (reintroduced in 2023)

This fund provides nurses caring for blood cancer patients up to £1,000 towards training, education or professional development that enhances the care of patients with leukaemia, MDS or MPN. This could be support with, attending a haematology conference or payment of a module that's part of a Masters degree in a relevant subject.

Volunteers

Our volunteers play a key role in ensuring that we can offer vital support to those affected by leukaemia, MDS or MPN. For some of our volunteers that involves working directly with those affected to provide support and guidance, for other volunteers it might be in supporting our fundraising goals or advising us on the information we produce. Each of our volunteers has their own unique experience and contributions, whether they are a patient, a clinician, a carer, or a supporter.

2023 has seen a continuation of the work we started in 2022, building our volunteering program to create a cohesive and highly valuable experience for all volunteers. This has involved continuing to build on the processes, training and support around each role, alongside including volunteers in new and exciting ways.

Our biggest volunteering involvement is our Buddy scheme, offering patients and carers one-to-one support with trained buddies who have themselves experienced leukaemia, MPN or MDS. The volunteers are DBS checked, trained and provided with ongoing support by both our volunteer coordinator and our Buddy coordinator, who is also a paid employee.

The newest role we have implemented for 2023 has been our Facebook Support Group Moderators. This is a group of volunteers who were given in depth training in moderation of online groups to allow them to support us in the running of three of our Facebook groups. The training included guidance on signposting, handling difficult conversations and safeguarding.

Patient and clinician volunteers have had a bigger involvement than ever with the reviewing of our patient information, both online and in print. They have been involved in the renewal of our CML and MDS information suites, as well as our new AML genetics booklet. We have increased the points which we get these volunteers involved, allowing them to influence decisions at a much earlier stage and continuing to feedback throughout the review process. In addition, we plan to review the format of our Patient Advisory Panel in 2024.

Our healthcare professional volunteers are a vital resource across the charity, they attend our medical advisory panels, review our patient information, and attend events with us. We are extremely grateful to all of these professionals, and the time they give. Included in this group are the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Co-ordinators who provide practical, emotional, and administrative support to the group.

Our community fundraising volunteers place collection tins, hold supermarket collections, run events, and join the cheer squad for the London Marathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. Our London Marathon cheer squads were particularly successful, we were able to get a large group of dental students involved in 2 different cheer squads, introducing Leukaemia Care to future clinical professionals, and giving them an insight into the work we are doing.

Our Unicornfest sculpture trail required a large input from volunteers in 2023, we recruited over 50 volunteers, most of whom had no existing connection to Leukaemia Care, to assist us in the event across the summer. Volunteers gave their time once or twice per week in our Unicornfest shop, assisting staff with selling official merchandise and unicorn themed goods. Over 30 volunteers got involved on a weekly basis in taking care of the unicorns whilst they were out in public, this involved them looking out for, reporting damage, and keeping their unicorn clean. This role allowed for family volunteering, with volunteers getting their children involved with helping them. We also made a connection with a team from Lloyds Bank who participated in a volunteering day of cleaning unicorns across the city and litter picking. The grand finale of Unicornfest saw us involve 43 volunteers in the Farewell Festival weekend.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Some feedback from our volunteers:

"It gives your cancer a sense of purpose a way to help others, fighting loneliness and misinformation... I've found LC very inclusive of physical and mental needs. Even more than I've expected. I'm physically disabled and neurodivergent and have always felt welcome at LC events and meetings." (Patient Advisory Panel Volunteer)

"It is very satisfying being able to help people and give something back after receiving so much from support charities and the NHS. There are not many positives to having leukaemia but being able to use one's personal experience to help others is definitely one." (Patient Advisor Panel and Buddy)

"To get me out and improve my mental health and wellbeing, the kids loved taking responsibility for the unicorn so was great they could be involved... Talking to others about our unicorn, I had so many friends asking different questions about the trail, shop or skating so I was able to bring a lot more people to the trail...do this with my kids. I normally miss out on a lot due to being a single mum with no childcare help" – (Unicornfest Mane-tainer Volunteer).

Risk assessment and management

A Serious Incident Report was submitted to the Charity Commission in January 2023 following a data breach which was also reported to the Information Commissioners Office (ICO). No further action was taken by either the ICO or the Charity Commission who were satisfied with Leukaemia Care's management of the issue.

We carry out an annual detailed review of the charity's activities and produce a comprehensive three-year strategic plan which sets out the major opportunities for the delivery of patient support. The Trustees monitor progress against the strategic objectives set out in the plan quarterly, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises:

- a comprehensive annual review to identify, where possible, the risks which the charity may face during the forthcoming year
- the establishment, where possible, of contingency plans to meet anticipated risk(s)
- the establishment of systems and procedures to mitigate such risks and the implementation of procedures to minimise any real or potential impact on the charity should any such risk(s) materialise
- the prioritisation of the charity's activities both actual and planned
- the preparation and monitoring of meaningful and timely financial and management information.

The strategic plan referred to above focuses on the delivery of care and support to anyone affected by blood cancer. Successful implementation of the plan is dependent upon the charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

But we have also put in place several other protections beyond this, including:

- Building organisational resilience – ensuring coverage of key skill sets, and developing existing staff within and beyond their roles
- Diversifying income – we have sought to create a wide range of income streams, to ensure we are less reliant on the London Marathon
- Phased investment – at present we have created plans for 2023 and 2024 which include a significant deficit as we seek to grow income.
- Regular review - by SMT at least monthly and quarterly at Trustee meetings

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our Reserves Policy

Leukaemia Care's reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the Charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term.

It is Leukaemia Care's policy to express reserves in terms of 'months of expenditure' for the purposes of external communications.

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

- i. Liabilities and contingencies - i.e. staffing costs to provide services, wind-down costs based on the costs of closing down the Charity.
- ii. Provision to absorb setback - i.e. predominantly related to income-based risk.
- iii. Funds designated for specific commitments – i.e. operational plan commitments, including forecast deficits or existing committed projects and activities.

In line with the considerations above, Leukaemia Care's policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure. Ongoing expenditure excludes one-off projects and depreciation, which are met through designation.

Our policy is subject to annual review by the board of Trustees, with the reserves reviewed in line with the policy at budget setting time and in time for the new financial year. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day-to-day investment management is delegated to an authorized, professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be available at short notice to support the on-going activities of Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, governance and management

Constitution

This is the fourth annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

Trustees and their role

The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 trustees in office at any one time are required by the constitution. At each AGM one-third of the trustees, must retire from office but may stand for re-election. A Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to trustee meetings. The trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr Christopher R G Matthews-Maxwell (Chair)

Mrs W J Davies (Treasurer)

Dr Emmanouil Nikolousis

Ms E Wilson (Vice Chair)

Ms Kate Stallard

Mr Robert Heppell

Mr Dharmesh Mehta

Professor Mhairi Copland

Ms Carina Patterson

Helen Knight

Dr Sarah Searle

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity's strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media outlets, online recruitment sites, specialist publications targeting for example healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, will be interviewed by the Chair and another trustee. Successful applicants will be co-opted as trustees until their formal election at the next annual general meeting.

On appointment, the new Trustees attend an induction at our offices in Worcester with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity's strategy as well as helpful publications such as the Charity Commissions "The essential trustee".

All Trustees are encouraged to attend Leukaemia Care's webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them, and how Leukaemia Care is addressing them.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our trading subsidiary

Ahead of the launch of our art trail Unicornfest, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its Directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest will go through the subsidiary company.

Senior management team

The Trustees delegate day-to-day operations of the charity to the executive team. In 2023, Zack resigned to take up a new role in the corporate sector, and Monica and Nicole stepped in as joint interim CEOs until Colin started in April 2024.

Chief Executive Officer (joined 2 April 2024)	Colin Dyer
Chief Executive Officer (left 30 November 2023)	Zack Pemberton-Whiteley
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Communications and Fundraising Director	Nicole Scully

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in activities such as chairing our conferences, contributing via our medical advisory panels, raising awareness of leukaemia and fundraising.

President	Dr Richard Taylor
Vice Presidents	Ms. Sue Merchant Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr Roland Maturi Mr Christopher Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2023*

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. Adele Fielding
Dr. Anthony Moorman
Prof. Oliver Ottmann
Dr. Nick Morley
Dr. Sara Ghorashian
Prof. Ajay Vora
Dr. Tobias Menne
Dr. Claire Rowntree

Acute myeloid leukaemia panel

Prof. Mary Frances McMullin
Dr. Steve Knapper
Prof. Rachael Hough (SCT adolescent leukaemia)
Dr. David Taussig
Dr. Priyanka Mehta (AML & CML)
Dr. Panagiotis Kottaridis
Dr. Mike Dennis
Dr. Ann-Louise Latif
Prof. Nigel Russell

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh
Prof. Chris Fegan
Prof. Guy Pratt
Assoc. Prof. Francesco Forconi
Prof. Adrian Bloor
Dr. Shankara Paneesha
Dr. Alison McCaig
Dr. Niamh Appleby
Dr. George Follows
Prof. Christopher Fox
Prof. John Gribben
Dr. Nicolas Martinez-Calle

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic
Prof. Jane Apperley
Prof. Stephen O'Brien
Prof. Mhairi Copeland
Dr Jonathan Kell
Dr. Nilima Parry-Jones
Dr. Piers Patten
Dr. Renata Walewska
Dr Sunil Lyengar

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2023*

Other blood cancers panel

Prof. Claire Harrison (MPN)
Dr. Claire Dearden (HCL)
Dr. Richard Kelly (Aplastic anaemia, MDS)
Prof David Bowen (MDS)
Dr Dima El-Shakari (LGLL, ALL, CLL)
Prof. Rachel Hough
Prof. Adam Mead

GP advisory Panel

Dr. Rebecca Chellaswamy
Dr. Elaine Hampton
Dr. Tom Kneale
Dr. Anish Kotecha
Dr. Lily Lamb
Dr. Rachael Marchant
Dr. Pawan Randev
Dr. Richard Roope
Dr. Lance Saker
Dr Sarah Smith (Searle)
Dr. Neil Smith
Dr. Sarah Taylor
Prof. David Weller

Nurse advisory panel

Sarah Blakey
Alicia Harris
Joanna Large
Catherine Langton
Sarah Watmough
Jacqueline Stones
Joanna Stokes
Alison Pugh
Phyllis Paterson
Lianne Palmer
Aileen Nield
Klara Matulay
Laura Ledger
Helen Knight
Caroline Kerr
Michelle Kenyon
Tracy Gunter
Catherine Griffiths
Kirsty Crozier
Marife Colis
Andrea Woollorton
Aine Sheerin
O'Neil Jackson
Alice Ryan
Bryony Tyrell
Claire Ballantyne
Sheri Thompson
Tina Brooks
Alison York
Matthew Fowler
Christina Kirby
Eleanor Pearce
Catherine Chapple

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively. When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

The Board of Trustees are responsible for setting remuneration levels for the senior management team; CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

The remuneration policy is reviewed annually by Trustees, normally at their meeting in November. Salaries are reviewed annually in March following annual appraisals and take effect from April. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health.

When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors:

- Mission and strategic aims of the charity and its general day-to-day needs.
- Consistency of equivalent roles across the charity and how any decision might impact on the overall remuneration policy.
- Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties.
- Current strategic business plan and how this might affect current and/or future needs.
- Leukaemia Care's financial ability to pay.
- Available information on charitable sector pay levels, alongside that of other sectors.
- Available information on regional pay levels
- The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development.
- The charity's track record in recruiting and retaining high-performing staff.
- The potential impact of any decision on the charity's reputation with beneficiaries, donors and the wider public.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

The Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the charity's remuneration policy and approach to senior management pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to the Senior Management Team, in line with the accounting Statement of Recommended Practice 2019 for charities. Given the charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

Related parties

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.


Auditor

In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The trustees' report was approved by the Board of Trustees.

DocuSigned by:

6CF4719F0E4E433...

.....
Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

7/4/2024

Date:

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charitable group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the 'charitable group') for the year ended 31 December 2023 which comprise the statements of financial activities, the balance sheets and the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable group's affairs as at 31 December 2023 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charitable group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable group's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the charitable group for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained
- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made
- a review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities
- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the charitable group

Audit response to risks identified

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material mis-statements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.


A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP

Chartered Accountants
Statutory Auditor

DocuSigned by:

058A9BD1D0D34B3...

.....
04/07/2024

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the charitable group by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

LEUKAEMIA CARE

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Notes							
<u>Income and endowments from:</u>							
Donations and legacies	3	591,126	249,151	840,277	836,570	341,404	1,177,974
Trading income	4	150,900	-	150,900	193,750	-	193,750
Fundraising income	5	1,237,052	-	1,237,052	723,517	-	723,517
Investments	6	34,057	-	34,057	43,352	-	43,352
Other income	7	963	-	963	901	-	901
Total income		2,014,098	249,151	2,263,249	1,798,090	341,404	2,139,494
<u>Expenditure on:</u>							
Raising funds	8	1,445,705	-	1,445,705	784,794	-	784,794
Charitable activities	9	1,158,403	256,727	1,415,130	937,681	257,067	1,194,748
Total expenditure		2,604,108	256,727	2,860,835	1,722,475	257,067	1,979,542
Net gains/(losses) on investments	15	30,632	-	30,632	(77,221)	-	(77,221)
Net (outgoing)/incoming resources		(559,378)	(7,576)	(566,954)	(1,606)	84,337	82,731
<u>Other recognised gains and losses</u>							
Revaluation of tangible fixed assets		12,640	-	12,640	12,640	-	12,640
Net movement in funds		(546,738)	(7,576)	(554,314)	11,034	84,337	95,371
Fund balances at 1 January 2023		2,971,488	155,918	3,127,406	2,960,454	71,581	3,032,035
Fund balances at 31 December 2023		2,424,750	148,342	2,573,092	2,971,488	155,918	3,127,406

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES - CHARITY INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Notes							
<u>Income and endowments from:</u>							
Donations and legacies	3	591,126	249,151	840,277	836,570	341,404	1,177,974
Fundraising income	5	1,237,052	-	1,237,052	794,529	-	794,529
Investments	6	34,057	-	34,057	43,352	-	43,352
Other income	7	963	-	963	901	-	901
Total income		1,863,198	249,151	2,112,349	1,675,352	341,404	2,016,756
<u>Expenditure on:</u>							
Raising funds	8	1,092,990	-	1,092,990	662,056	-	662,056
Charitable activities	9	1,158,403	256,727	1,415,130	937,681	257,067	1,194,748
Material other expenditure	14	202,130	-	202,130	-	-	-
Total expenditure		2,453,523	256,727	2,710,250	1,599,737	257,067	1,856,804
Net gains/(losses) on investments	15	30,632	-	30,632	(77,221)	-	(77,221)
Net (outgoing)/incoming resources		(559,693)	(7,576)	(567,269)	(1,606)	84,337	82,731
Other recognised gains and losses							
Revaluation of tangible fixed assets		12,640	-	12,640	12,640	-	12,640
Net movement in funds		(547,053)	(7,576)	(554,629)	11,034	84,337	95,371
Fund balances at 1 January 2023		2,971,488	155,918	3,127,406	2,960,454	71,581	3,032,035
Fund balances at 31 December 2023		2,424,435	148,342	2,572,777	2,971,488	155,918	3,127,406

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Fixed assets					
Tangible assets	17	887,448		879,550	
Investments	18	646,130		611,708	
			1,533,578		1,491,258
Current assets					
Stocks	20	8,435		35,404	
Debtors	21	306,117		407,042	
Investments	22	206,482		403,520	
Cash at bank and in hand		629,819		961,507	
		1,150,853		1,807,473	
Creditors: amounts falling due within one year	23	(111,339)		(171,325)	
Net current assets			1,039,514		1,636,148
Total assets less current liabilities			2,573,092		3,127,406
Income funds					
Restricted funds	25	148,342		155,918	
<u>Unrestricted funds</u>					
Designated funds	26	1,114,976		1,347,823	
General unrestricted funds		1,309,774		1,623,665	
			2,424,750		2,971,488
			2,573,092		3,127,406

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.


The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 26 June 2024.

DocuSigned by:

6CF4719F0E4E433...

.....
Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

DocuSigned by:

8FAD9028C739453...

.....
Mrs W J Davies (Treasurer)
Trustee

Company registration number 11911752

LEUKAEMIA CARE

CHARITY BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Fixed assets					
Tangible assets	17	887,448		879,550	
Investments	18	646,230		611,808	
			1,533,678		1,491,358
Current assets					
Stocks	20	8,435		6,225	
Debtors	21	301,802		396,851	
Investments	22	206,482		403,520	
Cash at bank and in hand		629,819		961,507	
			1,146,538		1,768,103
Creditors: amounts falling due within one year	23	(107,439)		(132,055)	
Net current assets			1,039,099		1,636,048
Total assets less current liabilities			2,572,777		3,127,406
Income funds					
Restricted funds	25	148,342		155,918	
<u>Unrestricted funds</u>					
Designated funds	26	1,114,976		1,347,823	
General unrestricted funds		1,309,459		1,623,665	
			2,424,435		2,971,488
			2,572,777		3,127,406

LEUKAEMIA CARE

CHARITY BALANCE SHEET (CONTINUED)
AS AT 31 DECEMBER 2023

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 26 June 2024.

DocuSigned by:
Chris Matthews-Maxwell
6CF4719F0E4E433...

.....
Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

DocuSigned by:
Wendy Davies
8FAD9028C739453...

.....
Mrs W J Davies (Treasurer)
Trustee

Company registration number 11911752

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	30		(525,632)		223,094
Investing activities					
Purchase of tangible fixed assets		(33,360)		(32,034)	
Purchase of investments		(118,518)		(69,247)	
Proceeds from disposal of investments		111,022		57,573	
Other investment movements		3,705		8,298	
Investment income received		34,057		40,580	
Net cash (used in)/generated from investing activities			(3,094)		5,170
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(528,726)		228,264
Cash and cash equivalents at beginning of year			1,365,027		1,136,763
Cash and cash equivalents at end of year			836,301		1,365,027
Relating to:					
Cash at bank and in hand			629,819		961,507
Short term deposits included in current asset investments			206,482		403,520

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charitable group's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable group is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charitable group. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination.

1.3 Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Leukaemia Care together with all entities controlled by the parent company (its subsidiaries).

All financial statements are made up to 31 December 2023. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group's financial statements from the date that control commences until the date that control ceases.

1.4 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable group has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies (Continued)

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charitable group.

1.6 Income

Income is recognised when the charitable group is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable group has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charitable group has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.7 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.8 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	Over 50 years
Computers and other equipment	over 3 or 4 years
Fixtures and fittings	over 10 years

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.9 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.10 Impairment of fixed assets

At each reporting end date, the charitable group reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.11 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.12 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.13 Financial instruments

The charitable group has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable group's balance sheet when the charitable group becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost. Financial assets classified as receivable within one year are not amortised.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligated to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charitable group's contractual obligations expire or are discharged or cancelled.

1.14 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charitable group is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charitable group's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by the review process.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

3 Donations and legacies Group and charity	Unrestricted funds		Restricted funds		Total		Unrestricted funds		Restricted funds		Total	
	2023	2023	2023	2023	2023	2023	2022	2022	2022	2022	2022	2022
	£	£	£	£	£	£	£	£	£	£	£	£
Donations and gifts	271,297	179,151	450,448	229,046	351,997	122,951	229,046	122,951	351,997	122,951	351,997	351,997
Legacies receivable	165,303	-	165,303	366,506	411,824	45,318	366,506	366,506	411,824	45,318	411,824	411,824
Corporate grants and donations	154,526	70,000	224,526	241,018	414,153	173,135	241,018	241,018	414,153	173,135	414,153	414,153
	591,126	249,151	840,277	836,570	1,177,974	341,404	836,570	836,570	1,177,974	341,404	1,177,974	1,177,974

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

4 Trading income Group

	Trading subsidiary 2023 £	Trading subsidiary 2022 £
Sales	150,900	193,750

5 Fundraising income Group

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Fundraising events	1,237,052	723,517

Charity

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Fundraising events	1,237,052	794,529

6 Investments Group and charity

	Unrestricted funds 2023 £	Unrestricted funds 2022 £
Rental income	6,475	25,900
Investment income	9,452	7,380
Interest receivable	18,130	10,072
	34,057	43,352

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

7 Other income Group and charity

Unrestricted funds	Unrestricted funds
2023	2022
£	£
Solar panels	901

8 Raising funds Group

Unrestricted funds	Unrestricted funds
2023	2022
£	£
<u>Fundraising and publicity</u>	
Staging fundraising events	198,534
Advertising	43,972
Other fundraising costs	73,022
Staff costs	284,286
Depreciation and impairment	4,564
Support costs	50,504
Fundraising and publicity	654,882
<u>Trading costs</u>	
Other trading activities	79,330
Staff costs	43,408
Support costs	3,170
Trading costs	125,908
<u>Investment management</u>	4,004
1,445,705	784,794

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

8 Raising funds

(Continued)

Charity

	Unrestricted funds	Unrestricted funds
	2023 £	2022 £
<u>Fundraising and publicity</u>		
Staging fundraising events	313,862	198,534
Advertising	48,883	43,972
Other fundraising costs	114,340	73,022
Staff costs	540,476	284,286
Depreciation and impairment	4,866	4,564
Support costs	59,767	50,504
	<hr/>	<hr/>
Fundraising and publicity	1,082,194	654,882
	<hr/>	<hr/>
<u>Trading costs</u>		
Support costs	5,135	3,170
	<hr/>	<hr/>
Trading costs	5,135	3,170
	<hr/>	<hr/>
<u>Investment management</u>	5,661	4,004
	<hr/>	<hr/>
	1,092,990	662,056
	<hr/>	<hr/>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

9 Charitable activities

	2023 £	2022 £
Staff costs	790,994	700,036
Depreciation and impairment	33,236	31,177
Patient Services costs	112,181	63,588
Conferences	2,126	2,256
Help Line costs	6,722	7,109
Leukaemia Matters/Nursing Matters	34,315	28,378
Campaign costs	76,151	42,683
Other charitable activities	6,685	18,913
Nurse e-learning tool	3,056	(1,081)
GP's e-learning tool	7,099	5,384
Other grants	155,500	168,054
Database costs	7,037	5,482
Patient Advocacy	1,481	(16,724)
Website costs	32,718	22,578
Other costs	9,159	2,842
	<u>1,278,460</u>	<u>1,080,675</u>
Share of support costs (see note 10)	124,689	106,677
Share of governance costs (see note 10)	11,981	7,396
	<u>1,415,130</u>	<u>1,194,748</u>
Analysis by fund		
Unrestricted funds	1,158,403	937,681
Restricted funds	256,727	257,067
	<u>1,415,130</u>	<u>1,194,748</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

10 Support costs Group and charity

	Support costs	Governance costs	2023	Support costs	Governance costs	2022
	£	£	£	£	£	£
Staff costs	22,157	-	22,157	16,753	-	16,753
Office costs	162,299	-	162,299	140,428	-	140,428
Audit fees	-	6,600	6,600	-	4,200	4,200
Legal and professional	-	3,419	3,419	-	3,298	3,298
Trustee and meeting expenses	-	7,097	7,097	-	3,068	3,068
	<u>184,456</u>	<u>17,116</u>	<u>201,572</u>	<u>157,181</u>	<u>10,566</u>	<u>167,747</u>
Analysed between						
Fundraising	59,767	-	59,767	50,504	-	50,504
Trading	-	5,135	5,135	-	3,170	3,170
Charitable activities	124,689	11,981	136,670	106,677	7,396	114,073
	<u>184,456</u>	<u>17,116</u>	<u>201,572</u>	<u>157,181</u>	<u>10,566</u>	<u>167,747</u>

Governance costs includes payments to the auditors of £6,600 (2022- £4,200) for audit fees, In addition included in the costs of other trading activities is £3,500 (2022 - £3,500) in respect of the audit of the financial statements of the subsidiary undertaking.

11 Auditor's remuneration

Fees payable to the charitable group's auditor and associates:	2023	2022
	£	£
Audit of the charitable group's annual accounts	<u>6,600</u>	<u>4,200</u>

In addition £3,500 is payable in respect of the audit of the subsidiary undertaking.

12 Trustees

The charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 (2022: 2) trustees for the current year were £5,748 (2022 : £2,521).

None of the trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arm's length basis and the amount paid during the year amounted to £3,069 (2022 : £2,186).

All trustees are covered by an indemnity insurance policy costing £844 (2022 : £819)

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

13 Employees

The average monthly number of employees during the year was:

	2023 Number	2022 Number
Training and provision of care	27	20
Fundraising and publicity	22	16
Accounts and administration	5	4
Total	54	40

Employment costs

	2023 £	2022 £
Wages and salaries	1,296,086	930,750
Social security costs	101,407	78,226
Other pension costs	47,095	35,507
	1,444,588	1,044,483

The remuneration of key management personnel through payroll and other fees is £204,181 (2022 : £190,032).

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2023 Number	2022 Number
£60,001 - £70,000	1	1

14 Material other expenditure

Material other expenditure is the write off of the loan with Leukaemia Care Trading Limited as this debt is no longer recoverable.

15 Net (losses)/gains on investments Group and charity

	Unrestricted funds	Unrestricted funds
	2023 £	2022 £
Revaluation of investments	24,702	(70,142)
Gain/(loss) on sale of investments	5,930	(7,079)
	30,632	(77,221)

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

15 Net (losses)/gains on investments

(Continued)

16 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

The subsidiary undertaking is required to Gift Aid profits arising to the parent charity such that no tax charge arises.

17 Tangible fixed assets Group and charity

	Freehold buildings	Computers and other equipment	Fixtures and fittings	Total
	£	£	£	£
Cost				
At 1 January 2023	842,599	276,673	14,656	1,133,928
Additions	-	33,360	-	33,360
Disposals	-	(183,869)	-	(183,869)
At 31 December 2023	842,599	126,164	14,656	983,419
Depreciation and impairment				
At 1 January 2023	-	241,993	12,385	254,378
Depreciation charged in the year	12,640	23,996	1,466	38,102
Eliminated in respect of disposals	-	(183,869)	-	(183,869)
Revaluation	(12,640)	-	-	(12,640)
At 31 December 2023	-	82,120	13,851	95,971
Carrying amount				
At 31 December 2023	842,599	44,044	805	887,448
At 31 December 2022	842,599	34,680	2,271	879,550

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

18 Fixed asset investments

Group

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2023	599,249	12,459	-	611,708
Additions	118,518	(118,518)	-	-
Valuation changes	24,702	-	-	24,702
Other cash movements	(212)	4,002	-	3,790
Loss on disposal	5,930	-	-	5,930
Disposals	(111,022)	111,022	-	-
At 31 December 2023	637,165	8,965	-	646,130
Carrying amount				
At 31 December 2023	637,165	8,965	-	646,130
At 31 December 2022	599,249	12,459	-	611,708

Charity

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2023	599,249	12,459	100	611,808
Additions	118,518	(118,518)	-	-
Valuation changes	24,702	-	-	24,702
Other cash movements	(212)	4,002	-	3,790
Loss on disposal	5,930	-	-	5,930
Disposals	(111,022)	111,022	-	-
At 31 December 2023	637,165	8,965	100	646,230
Carrying amount				
At 31 December 2023	637,165	8,965	100	646,230
At 31 December 2022	599,249	12,459	100	611,808

Other investments represents the interest in the subsidiary undertaking, see note 28.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

19 Financial instruments Group and charity

	2023 £	2022 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	637,165	599,249

20 Stocks

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Finished goods and goods for resale	8,435	35,404	8,435	6,225

21 Debtors

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Amounts falling due within one year:				
Trade debtors	53,646	183,372	51,266	42,572
Amounts owed by subsidiary undertakings	-	-	-	137,317
Other debtors	2,082	8,467	147	1,759
Prepayments and accrued income	250,389	215,203	250,389	215,203
	306,117	407,042	301,802	396,851

22 Current asset investments Group and charity

	2023 £	2022 £
Unlisted investments	206,482	403,520

23 Creditors: amounts falling due within one year

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Other taxation and social security	28,981	24,912	28,981	24,912
Trade creditors	22,137	66,584	22,137	31,064
Accruals and deferred income	60,221	79,829	56,321	76,079
	111,339	171,325	107,439	132,055

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2023*

24 Retirement benefit schemes

Defined contribution schemes

The charitable group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charitable group in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £47,095 (2022 - £35,507).

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds Group and charity

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 January 2022	Movement in funds		Balance at January 2023	Movement in funds		Balance at 31 December 2023
	£	Incoming resources	Resources expended ¹	£	Incoming resources	Resources expended	£
The Lily Blae Hope Fund	22,467	-	(13,083)	9,384	-	(9,384)	-
Information Booklets	23,587	-	(23,587)	-	5,985	-	5,985
GP e-learning tool	7,556	8,423	(15,979)	-	25,000	(25,000)	-
Nurse Advisor	-	30,346	(30,346)	-	-	-	-
Student/Education	5,000	-	-	5,000	-	(5,000)	-
Glasgow Area	-	1,900	(1,600)	300	10,000	(7,471)	2,829
Support Group - Scotland	4,510	-	(1,176)	3,334	-	(756)	2,578
Counselling Fund	-	10,005	(9,135)	870	15,000	(15,870)	-
Travel Grant	-	47,000	(47,000)	-	-	-	-
Support Group - Glasgow and Aberdeen	1,546	-	(588)	958	-	(958)	-
Support Group - South Shields	38	-	(38)	-	-	-	-
Support Group - Leicestershire	1,393	-	-	1,393	2,000	(278)	3,115
Birmingham Patient Conference	500	-	-	500	-	(500)	-
Welfare & Advocacy support	-	11,594	(11,594)	-	-	-	-
Belfast Hospital Support	2,000	9,999	-	11,999	-	-	11,999
Bristol Hospital Support	2,000	-	(869)	1,131	5,000	(5,725)	406
Financial Grants	-	-	-	-	60,000	(60,000)	-
Patient Conferences/Webinars	-	25,092	(25,092)	-	-	-	-
Care Helpline Costs	984	1,375	(2,359)	-	5,000	(5,000)	-
Nurse e-learning	-	3,175	(3,175)	-	-	-	-
Buddy Scheme	-	19,243	(19,243)	-	200	(200)	-
West Midlands Hospital Support	-	9,500	(9,500)	-	5,593	(5,593)	-
Spot Leukaemia	-	14,654	(14,654)	-	30,000	(30,000)	-

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

25	Restricted funds	(Continued)				
	Support Groups	-	5,851	(5,851)	-	-
	Newcastle Hospital Support	-	1,000	-	-	4,306
	UCHL Hospital Support	-	2,000	(985)	1,015	-
	Manchester Hospital Support	-	7,000	(2,974)	4,026	2,830
	Nottingham Hospital Support	-	9,454	-	9,454	11,454
	Patient Support Scotland	-	5,000	(5,000)	-	1,706
	William Davidson - Aberdeen Area	-	45,318	(800)	44,518	33,528
	CAR-T	-	20,000	(10,000)	10,000	-
	AML Information	-	15,000	-	15,000	-
	AML Education	-	23,135	-	23,135	-
	Yorkshire Patient Support	-	10,000	(1,654)	8,346	3,736
	Wales Hospital Support	-	3,965	-	3,965	3,611
	Support Group Wales	-	1,375	(785)	590	-
	Oxfordshire Hospital Support	-	-	-	-	2,000
	Support Group Leeds	-	-	-	-	1,040
	Good Hope Hospital Support	-	-	-	-	-
	Glasgow Hospital Support	-	-	-	-	7,000
	Northern Ireland Hospital Support	-	-	-	-	2,500
	NNUH Hospital Support	-	-	-	-	7,612
	Plymouth/Devon	-	-	-	-	9,049
	Cambridge	-	-	-	-	2,000
	Merseyside	-	-	-	-	6,000
	Swindon Hospital Supports	-	-	-	-	8,000
	Guy's & St Thomas Hospital Support	-	-	-	-	3,000
	Support Group Manchester	-	-	-	-	912
	Dorset (Bournemouth)	-	-	-	-	7,146
	Brighton	-	-	-	-	3,000
	Aberdeen	-	-	-	-	1,000
		71,581	341,404	(257,067)	155,918	249,151
						148,342

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds

(Continued)

The Lily Blae Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Worcester Support Group - to facilitate activities for the group.

Glasgow Area - funds to support services in the Glasgow area.

Kay Kendall - grant towards non-staff costs of helpline services

Support Group West Midlands - to facilitate activities for support groups in the area

Support Group Durham - to facilitate activities for the group.

Support Group Taunton - to facilitate activities for the group.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia

Travel Grant - to support people with the additional cost of travelling to hospital for treatment and monitoring appointments.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas

Support Group South Shields - to facilitate activities for support groups in these areas

Support Group Leicestershire - to facilitate activities for support groups in these areas

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds (Continued)

- Patient Support Worcestershire - to facilitate activities for support groups in this area
- Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham
- Welfare & Advocacy Support - in support of advocacy and welfare advise
- Belfast Hospital Support - in support of the costs in providing ward support
- Bristol Hospital Support - in support of the costs in providing ward support
- Staffing Costs - to support the employment costs of the Welfare and Advocacy Officers
- Patient conferences/webinars - grants in support of conferences held in the year.
- Care Helpline costs: this represents income received specifically to meet the costs of the Care line.
- Support Groups - to facilitate activities for local support groups
- Nurse e-learning - funds to support the advancement of knowledge in the nursing profession.
- Buddy Scheme - one to one support for patients
- West Midlands Hospital Support -to facilitate activities for local support groups
- Digital support - to support digital and information projects
- Support Group Cambridge - to facilitate activities for local support groups
- Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia
- CAR-T - offer grants and information to patients being treated with CAR-T.
- AML information - Providing a new suite of AML information.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds (Continued)

AML Education - Education of Healthcare Practitioners and patients on AML testing.

Yorkshire Support - to facilitate activities and support in this area.

Wales Hospital Support - in support of costs in providing ward support.

Support Group Wales - to facilitate activities for support groups in this area.

Oxfordshire Hospital Support - in support of costs in providing ward support

Support Group Leeds – to facilitate activities for support groups in this area

Good Hope Hospital Support - in support of costs in providing ward support

Glasgow Hospital Support - in support of costs in providing ward support

Northern Ireland Hospital Support - in support of costs in providing ward support

NNUH Hospital Support - in support of costs in providing ward support

Plymouth/Devon – to facilitate activities and support in this area

Cambridge - to facilitate activities and support in this area

Merseyside - to facilitate activities and support in this area

Swindon Hospital Support – in support of costs in providing ward support

Guy's & St Thomas' Hospital Support - in support of costs in providing ward support

Support Group Manchester - to facilitate activities for support groups in this area

Dorset - to facilitate activities and support in this area

Brighton - in support of costs in providing ward support

_____ Aberdeen - to facilitate activities and support in this area

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds

(Continued)

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

26 Designated funds Group and charity

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 January 2022	Transfers	Balance at 1 January 2023	Transfers	Balance at 31 December 2023
	£	£	£	£	£
Fixed asset fund	870,617	8,934	879,551	7,897	887,448
Strategic implemetation fund	216,510	251,762	468,272	(240,744)	227,528
	<u>1,087,127</u>	<u>260,696</u>	<u>1,347,823</u>	<u>(232,847)</u>	<u>1,114,976</u>

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the two-year strategy adopted by the Trustees on 31 January 2024.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

27 Analysis of net assets between funds Group

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2023 are represented by:						
Tangible assets	887,448	-	887,448	879,550	-	879,550
Investments	646,130	-	646,130	611,708	-	611,708
Current assets/(liabilities)	891,172	148,342	1,039,514	1,480,230	155,918	1,636,148
	<u>2,424,750</u>	<u>148,342</u>	<u>2,573,092</u>	<u>2,971,488</u>	<u>155,918</u>	<u>3,127,406</u>

Charity

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2023 are represented by:						
Tangible assets	887,448	-	887,448	879,550	-	879,550
Investments	646,130	-	646,130	611,708	-	611,708
Current assets/(liabilities)	890,857	148,342	1,039,199	1,480,230	155,918	1,636,148
	<u>2,424,435</u>	<u>148,342</u>	<u>2,572,777</u>	<u>2,971,488</u>	<u>155,918</u>	<u>3,127,406</u>

28 Related party transactions

The charity received £nil (2022 - £71,012) from the subsidiary undertaking under a Gift Aid arrangement. There were no other disclosable related party transactions during the year (2022 - none).

29 Subsidiaries

Details of the charitable group's subsidiaries at 31 December 2023 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held	% Held Direct Indirect
Leukaemia Care Trading Limited	England & Wales	Fundraising	Ordinary	100.00

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

30	Cash generated from operations	2023 £	2022 £
	(Deficit)/surplus for the year	(769,084)	82,731
	Adjustments for:		
	Investment income recognised in statement of financial activities	(34,057)	(43,352)
	(Gain)/loss on disposal of investments	(5,930)	7,079
	Fair value gains and losses on investments	(24,702)	70,142
	Depreciation and impairment of tangible fixed assets	38,103	35,741
	Movements in working capital:		
	Decrease/(increase) in stocks	26,969	(35,404)
	Decrease in debtors	303,055	12,466
	(Decrease)/increase in creditors	(59,986)	93,691
	Cash (absorbed by)/generated from operations	(525,632)	223,094
31	Analysis of changes in net funds		
	The charitable group had no debt during the year.		